tripelennamine (PBZ, Pyribenzamine, Pyrinamine, Stanzamine)

Introduction

Tradename: PBZ. (tripelennamine hydrochloride or citrate)

Indications

• perenial or seasonal allergies
  • allergic rhinitis, allergic conjunctivitis
  • nasal congestion, cough, sneezing, rhinorrhea
• other allergic conditions
  • urticaria, pruritus

Contraindications

• narrow-angle glaucoma
• bladder neck obstruction
• symptomatic prostatic hypertrophy
• stenosing peptic ulcer

Dosage

• adults
  • 25-50 mg PO every 4-6 hours
  • maximum 600 mg/day
  • extended release: 100 mg BID-TID
• infants & children
  • 5 mg/kg/day in 4-6 divided doses
  • maximum: 300 mg/day

Tabs: 50 mg.

Extended release: 100 mg.

Adverse effects

• common (> 10%)
  • drowsiness (slight to moderate)
  • thickening of bronchial secretions
• less common (1-10%)
  • headache, fatigue, increased appetite, increased weight, nervousness, dizziness, nausea, diarrhea, abdominal pain, dry mouth, pharyngitis, arthralgia
• uncommon (< 1%)
  • angioedema, bronchospasm, depression, edema, epistaxis, hepatitis, myalgia, palpitations, paresthesias, photosensitivity, rash, hypotension, sedation, paradoxical excitement, insomnia, tremor, blurred vision, urinary retention

• drug adverse effects of H1 receptor antagonists

Laboratory

• specimen: serum
• methods: GLC
• labs with Loincs
  • tripelennamine in blood
  • tripelennamine in gastric fluid
  • tripelennamine in serum/plasma
  • tripelennamine in serum/plasma/urine
  • tripelennamine in urine

More general terms

• H1 receptor antagonist (antihistamine)
• ethylenediamine

Component of

• diphenhydramine/tripelennamine

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5587
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9066
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=197066
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=657216